{"classes":[{"categories":[{"measurements":[{"comment":"Since the primary endpoint of statistically significant improvement in PFS was not met patients are not being followed for OS. The upper bound of the confidence interval is not estimable by the Kaplan-Meier analysis due to the short follow-up time.","groupId":"OG000","lowerLimit":"19.2","upperLimit":"NA","value":"19.2"},{"comment":"Since the primary endpoint of statistically significant improvement in PFS was not met patients are not being followed for OS. The upper bound of the confidence interval is not estimable by the Kaplan-Meier analysis due to the short follow-up time.","groupId":"OG001","lowerLimit":"15.8","upperLimit":"NA","value":"17.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"240"},{"groupId":"OG001","value":"236"}],"units":"Participants"}],"description":"To evaluate overall survival (OS) in patients with advanced GIST treated with avapritinib compared to patients treated with regorafenib","dispersionType":"95% Confidence Interval","groups":[{"description":"300 mg PO QD avapritinib: Avapritinib tablets for oral administration. Avapritinib will be dosed at 300 mg once daily, continuously.","id":"OG000","title":"Avapritinib"},{"description":"160 mg PO QD regorafenib: Regorafenib tablets for oral administration. Regorafenib will be dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).","id":"OG001","title":"Regorafinib"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"24 Months","title":"Overall Survival (OS) in Patients With Advanced GIST Treated With Avapritinib Compared to Patients Treated With Regorafenib","type":"SECONDARY","unitOfMeasure":"months"}